Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR2)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There are many medications available for the treatment of high blood pressure (hypertension), but finding the right one for a specific patient can be challenging. In fact, it is estimated that less than 50% of people with hypertension have their blood pressure under control. The hypothesis is that genetic differences between individuals influence their response to antihypertensive medications. This study is aimed at determining the genetic factors that may influence a person's response to either a beta-blocker or a thiazide diuretic. The hope is that through this research, the investigators may someday be able to use an individual's genetic information to guide the selection of their blood pressure medicine, leading to better control of blood pressure, and less need for the current trial and error process.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertension |
Drug: metoprolol or chlorthalidone |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Pharmacogenomic Evaluation of Antihypertensive Responses 2 |
- antihypertensive response [ Time Frame: after 6-8 weeks of treatment ] [ Designated as safety issue: No ]antihypertensive response will be assessed by measuring blood pressure before and after treatment
- adverse metabolic effects [ Time Frame: after 6-8 weeks treatment ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 400 |
| Study Start Date: | August 2010 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: metoprolol |
Drug: metoprolol or chlorthalidone
metoprolol 50 mg twice daily titrated to 100 mg twice daily chlorthalidone 15 mg daily titrated to 25 mg daily Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.
|
| Experimental: chlorthalidone |
Drug: metoprolol or chlorthalidone
metoprolol 50 mg twice daily titrated to 100 mg twice daily chlorthalidone 15 mg daily titrated to 25 mg daily Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily.
|
Detailed Description:
The proposed work should help move toward the long-term goal of selection of antihypertensive drug therapy based on a patient's genetic make-up. Hypertension (HTN) is the most common chronic disease for which drugs are prescribed, and the most prevalent risk factor for heart attack, stroke, renal failure and heart failure. Responses to antihypertensive drug therapy exhibit considerable interpatient variability, contributing to poor rates of HTN control (currently about 40-50% in the US), and frequent nonadherence and dropout from therapy. We propose to identify genetic predictors of the antihypertensive and adverse metabolic responses to two preferred and pharmacodynamically contrasting drugs, a beta-blocker (metoprolol) and a thiazide diuretic (chlorthalidone) in a sequential monotherapy design in 400 hypertensive individuals. Data collected will include home and clinic blood pressure, blood samples for testing for adverse metabolic effects and other biomarkers, RNA, and DNA and urine sample. We will conduct genome-wide association SNP genotyping and data from the study will be used for replication of findings from the previous PEAR trial, along with new discoveries. The primary aims are to define the genetic determinants of the antihypertensive response and adverse metabolic responses (e.g. changes in glucose, triglycerides and uric acid). The proposed research is significant because genetically-targeted antihypertensive therapy could lead to dramatically higher response rates and fewer adverse effects than the usual trial-and-error approach. This would likely lead to higher rates of HTN control, less need for polypharmacy, reduced health care costs, and improved outcomes.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- An average seated home DBP > 85 mmHg and < 110 mmHg and home SBP < 180 mmHg.
- Subjects must also have an average seated (> 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP < 180 mmHg
Exclusion Criteria:
- Secondary forms of HTN (including sleep apnea)
- Isolated systolic HTN
- Other diseases requiring treatment with BP lowering medications
- Heart rate < 55 beats/min (for metoprolol only)
- Known cardiovascular disease (including history of angina pectoris, heart failure, presence of a cardiac pacemaker, history of myocardial infarction or revascularization procedure, or cerebrovascular disease, including stroke and TIA)
- Diabetes mellitus (Type 1 or 2)
- Renal insufficiency (serum creatinine > 1.5 in men or 1.4 in women)
- Primary renal disease
- Pregnancy or lactation
- Liver enzymes > 2.5 upper limits of normal
- Current treatment with NSAIDS, COX2-inhibitors, oral contraceptives or estrogen.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01203852
| United States, Florida | |
| University of Florida | |
| Gainesville, Florida, United States, 32610 | |
| United States, Georgia | |
| Emory University | |
| Atlanta, Georgia, United States | |
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States | |
| Principal Investigator: | Julie A Johnson, PharmD | University of Florida |
More Information
Additional Information:
No publications provided
| Responsible Party: | Dr. Julie A Johnson, Principal Investigator, National Institute of General Medical Sciences (NIGMS) |
| ClinicalTrials.gov Identifier: | NCT01203852 History of Changes |
| Other Study ID Numbers: | U01 GM074492-06 |
| Study First Received: | September 15, 2010 |
| Last Updated: | October 15, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of General Medical Sciences (NIGMS):
|
hypertension antihypertensive drug pharmacogenetics |
genetics blood pressure glucose |
Additional relevant MeSH terms:
|
Hypertension Cardiovascular Diseases Vascular Diseases Antihypertensive Agents Chlorthalidone Metoprolol Adrenergic Agents Adrenergic Antagonists Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Anti-Arrhythmia Agents Autonomic Agents |
Cardiovascular Agents Diuretics Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Neurotransmitter Agents Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Sympatholytics Therapeutic Uses |
ClinicalTrials.gov processed this record on February 27, 2015